Alonso Gutiérrez Romero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alonso Gutiérrez Romero has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Anaclara Michel-Chávez
Department of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
1 shared publication - Antonio Arauz
Stroke Clinic, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suarez, Mexico City, Mexico
1 shared publication Anwar Garcia Santos
1 shared publicationArturo Cadena‐Fernández
Department of Neurology and Psychiatry Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City Mexico
1 shared publication- Elma Paredes-Aragón
Department of Neurology, National Institute of Neurology and Neurosurgery, Mexico City, Mexico
1 shared publication - Elvira Castro Martínez
Emergency Department, Instituto Nacional de Neurología y Neurocirugía “Dr. Manuel Velasco Suárez”, Mexico City, Mexico
1 shared publication
Latest Publications
- Open Access
- 17 July 2023
- Published by Instituto Mexicano del Seguro Social in Archivos de Neurociencias
- Vol. 29 (2)
Implementación del código estado epiléptico en México: tiempo es cerebro
Introducción: El estado epiléptico es una urgencia neurológica. Se calcula una incidencia de 61 casos por 100,000 habitantes/año. Se estima una mortalidad entre el 20% y el 80%, siendo altamente dependiente de la eficacia y rapidez del manejo, la etiología y los factores de riesgo. Métodos: En esta síntesis narrativa, los autores revisaron la evidencia científica actual y elaboraron una propuesta de expertos para el manejo adaptada para México. Resultados y discusión: Sintetizamos los datos actuales de la evidencia médica para estado epiléptico, con un enfoque practico para la mejora del manejo de los pacientes con estado epiléptico. Conclusión: Los pacientes con estado epiléptico deben tratarse de forma estandarizada para prevenir morbimortalidad y utilizar de forma estandarizada un electroencefalograma continuo.
- 17 July 2023
- Published by Instituto Mexicano del Seguro Social in Archivos de Neurociencias
- Vol. 29 (2)
Open AccessImplementación del código estado epiléptico en México: tiempo es cerebro
Introducción: El estado epiléptico es una urgencia neurológica. Se calcula una incidencia de 61 casos por 100,000 habitantes/año. Se estima una mortalidad entre el 20% y el 80%, siendo altamente dependiente de la eficacia y rapidez del manejo, la etiología y los factores de riesgo. Métodos: En esta síntesis narrativa, los autores revisaron la evidencia científica actual y elaboraron una propuesta de expertos para el manejo adaptada para México. Resultados y discusión: Sintetizamos los datos actuales de la evidencia médica para estado epiléptico, con un enfoque practico para la mejora del manejo de los pacientes con estado epiléptico. Conclusión: Los pacientes con estado epiléptico deben tratarse de forma estandarizada para prevenir morbimortalidad y utilizar de forma estandarizada un electroencefalograma continuo.
- 2 August 2022
- Published by Wiley in European Journal of Neurology
- Vol. 29 (11) , 3368-3379
Incidence of Guillain–Barré syndrome following SARS‐CoV‐2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines
Background and purpose: Information on Guillain–Barré syndrome (GBS) as an adverse event following immunization (AEFI) against SARS‐CoV‐2 remains scarce. We aimed to report GBS incidence as an AEFI among adult (≥18 years) recipients of 81,842,426 doses of seven anti‐SARS‐CoV‐2 vaccines between December 24, 2020, and October 29, 2021, in Mexico.Methods: Cases were retrospectively collected through passive epidemiological surveillance. The overall observed incidence was calculated according to the total number of administered doses. Vaccines were analyzed individually and by vector as mRNA‐based (mRNA‐1273 and BNT162b2), adenovirus‐vectored (ChAdOx1 nCov‐19, rAd26‐rAd5, Ad5‐nCoV, and Ad26.COV2‐S), and inactivated whole‐virion‐vectored (CoronaVac) vaccines.Results: We identified 97 patients (52 males [53.6%]; median [interquartile range] age 44 [33–60] years), for an overall observed incidence of 1.19/1,000,000 doses (95% confidence interval [CI] 0.97–1.45), with incidence higher among Ad26.COV2‐S (3.86/1,000,000 doses, 95% CI 1.50–9.93) and BNT162b2 recipients (1.92/1,00,000 doses, 95% CI 1.36–2.71). The interval (interquartile range) from vaccination to GBS symptom onset was 10 (3–17) days. Preceding diarrhea was reported in 21 patients (21.6%) and mild COVID‐19 in four more (4.1%). Only 18 patients were tested for Campylobacter jejuni (positive in 16 [88.9%]). Electrophysiological examinations were performed in 76 patients (78.4%; axonal in 46 [60.5%] and demyelinating in 25 [32.8%]); variants were similar across the platforms. On admission, 91.8% had a GBS disability score ≥3. Seventy‐five patients (77.3%) received intravenous immunoglobulin, received seven plasma exchange (7.2%), and 15 (15.5%) were treated conservatively. Ten patients (10.3%) died, and 79.1% of survivors were unable to walk independently.Conclusions: Guillain–Barré syndrome was an extremely infrequent AEFI against SARS‐CoV‐2. The protection provided by these vaccines outweighs the risk of developing GBS.
- 2 August 2022
- Published by Wiley in European Journal of Neurology
- Vol. 29 (11) , 3368-3379
Incidence of Guillain–Barré syndrome following SARS‐CoV‐2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines
Background and purpose: Information on Guillain–Barré syndrome (GBS) as an adverse event following immunization (AEFI) against SARS‐CoV‐2 remains scarce. We aimed to report GBS incidence as an AEFI among adult (≥18 years) recipients of 81,842,426 doses of seven anti‐SARS‐CoV‐2 vaccines between December 24, 2020, and October 29, 2021, in Mexico.Methods: Cases were retrospectively collected through passive epidemiological surveillance. The overall observed incidence was calculated according to the total number of administered doses. Vaccines were analyzed individually and by vector as mRNA‐based (mRNA‐1273 and BNT162b2), adenovirus‐vectored (ChAdOx1 nCov‐19, rAd26‐rAd5, Ad5‐nCoV, and Ad26.COV2‐S), and inactivated whole‐virion‐vectored (CoronaVac) vaccines.Results: We identified 97 patients (52 males [53.6%]; median [interquartile range] age 44 [33–60] years), for an overall observed incidence of 1.19/1,000,000 doses (95% confidence interval [CI] 0.97–1.45), with incidence higher among Ad26.COV2‐S (3.86/1,000,000 doses, 95% CI 1.50–9.93) and BNT162b2 recipients (1.92/1,00,000 doses, 95% CI 1.36–2.71). The interval (interquartile range) from vaccination to GBS symptom onset was 10 (3–17) days. Preceding diarrhea was reported in 21 patients (21.6%) and mild COVID‐19 in four more (4.1%). Only 18 patients were tested for Campylobacter jejuni (positive in 16 [88.9%]). Electrophysiological examinations were performed in 76 patients (78.4%; axonal in 46 [60.5%] and demyelinating in 25 [32.8%]); variants were similar across the platforms. On admission, 91.8% had a GBS disability score ≥3. Seventy‐five patients (77.3%) received intravenous immunoglobulin, received seven plasma exchange (7.2%), and 15 (15.5%) were treated conservatively. Ten patients (10.3%) died, and 79.1% of survivors were unable to walk independently.Conclusions: Guillain–Barré syndrome was an extremely infrequent AEFI against SARS‐CoV‐2. The protection provided by these vaccines outweighs the risk of developing GBS.